Download PDF
Thromb Haemost 1967; 17(01/02): 165-175
DOI: 10.1055/s-0038-1654091
Originalarbeiten - Original Articles - Travaux Originaux
Schattauer GmbH

Hypercoagulable State Induced in Humans by the Intravenous Administration of Purified Ellagic Acid

A Girolami   *
1   “Clotting Mechanisms” Section, Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, New York
,
E. E Cliffton
1   “Clotting Mechanisms” Section, Memorial Sloan-Kettering Cancer Center and Cornell University Medical College, New York
› Author AffiliationsThis work was supported by Grant No. C-3817 of the N. C. I. and No. H-2867 of the N. H. I. and institutional funds.
Further Information

Publication History

Publication Date:
26 June 2018 (online)

    Permissions and Reprints

Summary

The intravenous administration of ellagic acid induces a hypercoagulable state in humans. This is characterized by a striking shortening of the silicone clotting time and moderate shortening of the glass clotting time. No change in other coagulation parameter was noted. However, in one patient with a prolonged thromboplastin generation test, a correction of same was observed. The effect of ellagic acid is more prolonged in humans than in animals. There was no obvious toxic reaction to the administration of the drug.

* Visiting Research Fellow, Sloan-Kettering Institute for Cancer Research, New York, New York. Permanent address: Institute of “Semeiotica Medica” (Head: Prof. M. Austoni), University of Padua Medical School, Padua, Italy.

* Associate Member, Sloan-Kettering Institute for Cancer Reasearch, New York, New York.


 

  • References

  • 1 Alexander B. Blood coagulation and thrombotic disease. Circulation 25: 872 1962;
    CrossrefPubMedGoogle Scholar
  • 2 Sise H. S, Moschos C. B, Becker B. On the nature of hypercoagulability. Amer. J. Med 33: 667 1962;
    CrossrefPubMedGoogle Scholar
  • 3 Owen C. A. Hypercoagulability and thrombosis. Mayo Clin. Proc 40: 830 1965;
    PubMedGoogle Scholar
  • 4 Edwards E. A. Thrombophlebitis associated with carcinoma. New Engl. J. Med 240: 1031 1949;
    CrossrefPubMedGoogle Scholar
  • 5 Kenney W. E. Association of carcinoma in the body and tail of the pancreas with multiple venous thrombi. Surgery 14: 600 1943;
    PubMedGoogle Scholar
  • 6 Anlyan W. G, Shingleton W. W, DeLaughter G. D. Significance of idiopathic venous thrombosis and hidden cancer. J. A. M. A 161: 964 1956;
    CrossrefPubMedGoogle Scholar
  • 7 Lieberman J. S, Borrero J, Undaneta E, Wright I. S. Thrombophlebitis and cancer. J. A. M. A 177: 542 1961;
    CrossrefPubMedGoogle Scholar
  • 8 Wright I. S, Marple G. D, Beck D. F. Myocardial infarction, its clinical manifestations and treatment with anticoagulants. A study of 1,031 cases. Grune & Stratton; Inc. New York: 1954
    Google Scholar
  • 9 Duguid J. B. Thrombosis as a factor in the pathogenesis of aortic atherosclerosis. J. Path. Bact 60: 57 1948;
    CrossrefPubMedGoogle Scholar
  • 10 Murphy E. A, Mustard J. F. Coagulation tests and platelet economy in atherosclerotic and control subjects. Circulation 25: 114 1962;
    CrossrefPubMedGoogle Scholar
  • 11 Gurewich V, Grinspoon L. Blood coagulation in pregnancy: proconvertion and prothrombin and the hypercoagulable state. New Engl. J. Med 254: 358 1956;
    CrossrefPubMedGoogle Scholar
  • 12 Pechet L, Alexander B. Increased clotting factors in Pregnancy. New Engl. J. Med 265: 1093 1961;
    CrossrefPubMedGoogle Scholar
  • 13 Wright H. P. Changes in the adhesiveness of blood platelets following parturition and surgical operations. J. Path. Bact 54: 461 1942;
    CrossrefPubMedGoogle Scholar
  • 14 Warren R. Postoperative thrombophilia. New Engl. J. Med 249: 99 1953;
    CrossrefPubMedGoogle Scholar
  • 15 Cosgriff S. W, Diefenbach A. F, Vogt W. Hypercoagulability of the blood associated with ACTH and cortisone therapy. Amer. J. Med 9: 752 1950;
    CrossrefPubMedGoogle Scholar
  • 16 Keys A, Buzina R, Grande E, Anderson J. T. Effects of meals of different fats on blood coagulation. Circulation 15: 274 1957;
    CrossrefPubMedGoogle Scholar
  • 17 Greig H. B. W. Inhibition of fibrinolysis by alimentary lipaemia. Lancet II: 16 1956;
    PubMedGoogle Scholar
  • 18 Koszewski B. J, Vahabzadeh H. Hypercoagulability syndrome due to heparin co-factor deficiency. Thrombos. Diathes. haemorrh. (Stuttg.) 11: 485 1964;
    PubMedGoogle Scholar
  • 19 Ratnoff O. D, Grum J. D. Activation of Hageman Factor by solutions of ellagic acid. J. Lab. clin. Med 63: 359 1964;
    PubMedGoogle Scholar
  • 20 Botti E. E, Ratnoff O. D. Studies on the pathogenesis of thrombosis; An experimental hypercoagulable state induced by the intravenous injection of ellagic acid. J. Lab. Clin. Med 154: 385 1964;
    PubMedGoogle Scholar
  • 21 Girolami A, Agostino D, Cliffton E. E. The effect of ellagic acid on coagulation in vivo . Blood 27: 93 1966;
    PubMedGoogle Scholar
  • 22 Cliffton E. E, Agostino D, Girolami A. Prevention of traumatic bleeding in rats by ellagic acid. Proc. Soc. exp. Biol. (N. Y.) 120: 179 1965;
    CrossrefPubMedGoogle Scholar
  • 23 Cliffton E. E, Girolami A, Agostino D. The effect of ellagic acid on the thrombin induced hemorrhagic syndrome in the rat. Blood 28: 253 1966;
    PubMedGoogle Scholar
  • 24 Lee R. I, White P. D. A clinical study of the coagulation of blood. Amer. J. Med 145: 495 1913;
    PubMedGoogle Scholar
  • 25 Quick A. J. The physiology and pathology of hemostasis. Lea & Febiger; Philadelphia: 1951
    Google Scholar
  • 26 Lewis J. H, Ferguson J. H, Fresh J. W, Zucker M. B. Primary hemorrhagic diseases. J. Lab. clin. Med 49: 211 1957;
    PubMedGoogle Scholar
  • 27 Langdell R. D, Wagner R. H, Brinkhous K. M. Effect of antihemophilic factor on one-stage clotting tests. A presumptive test for hemophilia and a simple one-state anti-hemophilic factor assay procedure. J. Lab. clin. Med 41: 637 1953;
    PubMedGoogle Scholar
  • 28 Hardisty R. M, MacPherson J. C. A one-stage factor VIII (antihemophilic globulin) assay and its use on venous and capillary plasma. Thrombos. Diathes. haemorrh. (Stuttg.) 7: 215 1962;
    PubMedGoogle Scholar
  • 29 Hicks N. D, Pitney W. R. A rapid screening test for disorders of thromboplastin generation. Brit. J. Haemat 3: 237 1957;
    PubMedGoogle Scholar
  • 30 Mootse G, Agostino D, Cliffton E. E. Alterations in fibrinogen, plasminogen and inhibitors of plasmin with the growth of V2 carcinoma in rabbits. J. nat. Cancer Inst 35: 568 1965;
    PubMedGoogle Scholar
  • 31 Cliffton E. E, Cannamela D. A. Fibrinolytic and proteolytic activity of human plasminogen prepared from fraction III of human plasma. J. appl. Physiol 6: 42 1953;
    CrossrefPubMedGoogle Scholar
  • 32 Downie G. R, Cliffton E. E. A method for assay of serum proteolytic activity. Proc. Soc. exp. Med. (N. Y.) 71: 138 1949;
    CrossrefPubMedGoogle Scholar
  • 33 Spaet T. H, Horowitz H. I, Zucker-Franklin D, Cintron J, Bierenski J. J. Reticuloendothelial clearance of blood thromboplastin by rats. Blood 17: 196 1961;
    PubMedGoogle Scholar
  • 34 Niewiarowski S, Prou-Wartelle O. Rôle du facteur contact (facteur Hageman) dans le fibrinolyse. Thrombos. Diathes. haemorrh. (Stuttg.) 3: 593 1959;
    PubMedGoogle Scholar
  • 35 Iatridis S. G, Ferguson J. H. Effect of surface and Hageman factor on the endogenous or spontaneous activation of the fibrinolytic system. Thrombos. Diathes. haemorrh. (Stuttg.) 6: 411 1961;
    PubMedGoogle Scholar
  • 36 Iatridis S. G, Ferguson J. H. Active Hageman factor. A plasma lysokinase of the human fibrinolytic system. J. clin. Invest 41: 1277 1962;
    CrossrefPubMedGoogle Scholar
  • 37 Thomas D. P, Wessler S, Reimer S. M. The relation of factors XII, XI and IX to hypercoagulable states. Thrombos. Diathes. haemorrh. (Stuttg.) 9: 90 1963;
    PubMedGoogle Scholar
  • 38 Soulier J. P, Prou-Wartelle O, Ménaché D. Hageman trait and PTA deficiency. The role of contact of blood with glass. Brit. J. Haemat 5: 121 1959;
    CrossrefPubMedGoogle Scholar
  • 39 Waaler B. A. Contact activation in the intrinsic blood clotting system. University Press; Oslo: 1959
    Google Scholar
  • 40 Soulier J. P, Prou-Wartelle O. New data on Hageman factor and plasma thromboplastin antecedent. The role of contact in the initial phase of blood coagulation. Brit. J. Haemat 6: 88 1960;
    CrossrefPubMedGoogle Scholar
  • 41 Girolami A, Cliffton E. E. Unpublished observations.
    PubMed
  • 42 Cliffton E. E, Girolami A. The role of ellagic acid infusions in the management of bleeding conditions with different etiology. (In preparation.)
    PubMedGoogle Scholar